Biotech

All Articles

Amgen reports very first period 3 win for $400M dermatitis medication

.Amgen has shared (PDF) the very first stage 3 records on its $400 thousand eczema medication, linki...

Biogen, UCB file period 3 lupus succeed after stopping working earlier test

.Biogen and UCB's depend advancing into period 3 on the back of a failed research looks to have paid...

Aptadir really hopes brand new RNA preventions can easily reverse difficult cancers cells

.Italian biotech Aptadir Rehabs has released with the commitment that its own pipe of preclinical RN...

Wave surfs DMD excellence to regulators' doors, delivering stockpile

.Surge Life Sciences has actually fulfilled its own target in a Duchenne muscle dystrophy (DMD) rese...

Sanofi plucks brand new CSO from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma crease, usin...

Achilles drops cell therapy program, prepares for discharges after overlooking 'commercial practicality' objectives

.Achilles Therapies has actually shreded its tactic. The English biotech is knocking off on its own ...

Aligos heralds stage 2 MASH gain, slashing liver excess fat up to 46%

.Aligos Therapies is actually heralding a midstage win in metabolic-dysfunction connected steatohepa...

Basilea credit ratings $268M BARDA financing for antifungals, prescription antibiotics

.Basilea Pharmaceutica's job developing brand new antifungals has received a considerable increase c...

Capricor markets Europe legal rights to late-stage DMD treatment for $35M

.Possessing already scooped up the U.S. liberties to Capricor Therapeutics' late-stage Duchenne musc...

FDA fragments adcomm for Applied's uncommon ailment drug

.After dismissing the decision meeting for Applied Rehabs' metabolic disorder medicine govorestat, t...